All stock lists
NervGen Pharma Corp. (NASDAQ:NGEN)
CA · Delayed Price · Currency is USD
Also listed: NGENF, NGEN.VHealthcare · Biotechnology
$1.64+$0.01 (+0.61%)
Market cap
$176M
Insider Score
Health Score
Analyst consensus
Listed since
Feb 8, 2021
Website
Insider Score
––Not scored
NGEN Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From NGEN’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$67.6M
- Net margin
- —
Leverage20 / 20
Little or no net debt.
- Total debt
- $0
- Cash
- $86.9M
- Debt / equity
- 0.00
Liquidity10 / 20
Covers near-term obligations, without much room.
- Current assets
- $90.0M
- Current liabilities
- $73.0M
- Current ratio
- 1.23
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$29.6M
- Free cash flow
- -$29.6M
Dilution & runway0 / 20
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 92.4M
- Share growth (1y)
- 28.5%
- Cash runway
- 35 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
NGEN Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | $14.32 K | $14.18 K | -$29.95 K | $13.97 K | $14.02 K | $13.87 K |
| Gross Profit | -$14.32 K | -$14.18 K | $29.95 K | -$13.97 K | -$14.02 K | -$13.87 K |
| SG&A Expense | $4.42 M | $2.71 M | $5.18 M | $1.73 M | $3.78 M | $2.86 M |
| R&D Expense | $8.09 M | $4.93 M | $6.56 M | $4.44 M | $2.71 M | $3.13 M |
| Operating Expenses | $12.51 M | $7.64 M | $11.73 M | $6.17 M | $6.49 M | $5.99 M |
| Operating Income | -$12.52 M | -$7.66 M | -$11.70 M | -$6.18 M | -$6.50 M | -$6.00 M |
| Pretax Income | -$29.99 M | -$1.70 M | -$31.70 M | -$4.16 M | -$9.15 M | -$3.93 M |
| Tax Provision | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$29.99 M | -$1.70 M | -$31.70 M | -$4.16 M | -$9.15 M | -$3.93 M |
| EPS (Basic) | -$0.33 | -$0.02 | -$0.44 | -$0.06 | -$0.13 | -$0.06 |
| EPS (Diluted) | -$0.33 | -$0.02 | -$0.44 | -$0.06 | -$0.13 | -$0.06 |
| Shares Outstanding | 92.44 M | 79.90 M | 72.33 M | 73.16 M | 71.96 M | 70.67 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.